Lv2
140 积分 2024-01-24 加入
RECIST 1.1—Update and clarification: From the RECIST committee
14小时前
已完结
Spatial immune scoring system predicts hepatocellular carcinoma recurrence
27天前
已完结
Roles of intestinal microbiota in response to cancer immunotherapy
2个月前
已完结
Update on novel validly published and included bacterial taxa derived from human clinical specimens and taxonomic revisions published in 2023
2个月前
已完结
Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients
2个月前
已完结
The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma
3个月前
已完结
The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials
3个月前
已完结
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
3个月前
已完结
The influence of microbiota on the efficacy and toxicity of immunotherapy in cancer treatment
3个月前
已完结
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
3个月前
已完结
皖公网安备34019202002308
